William Vermi

Adaptive immunity maintains occult cancer in an equilibrium state

Lloyd J. Old, Mark J. Smyth, Robert D. Schreiber, 2007, Nature.

Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.

W. Vermi, Alfredo Berruti, E. Roca, 2019, Lung cancer.

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

Mark J. Smyth, Robert D. Schreiber, R. Schreiber, 2012, The Journal of experimental medicine.

BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction

Antonio Lanzavecchia, A. Lanzavecchia, M. Colonna, 2001, The Journal of experimental medicine.

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.

A. Zaniboni, W. Vermi, P. Bertocchi, 2014, Reviews on recent clinical trials.